ImmunityBio, Inc.
corporate_fare Company Profile
ImmunityBio, Inc. (NASDAQ:IBRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for IBRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for IBRX spans SCHEDULE 13D/A, 10-Q, 8-K, DEF 14A.
Recent high-impact activity:
- ImmunityBio Q2 Revenue Revised to $51.2M, Targets 2026 sBLA for Bladder Cancer
- Soon-Shiong Tightens Grip on ImmunityBio as Stake Climbs to 64.8%
- ImmunityBio Q2 Revenue Jumps 92% but Going Concern Warning and $672M in Non-Cash Fair Value Losses Drive $863M Net Loss
- ImmunityBio Posts Record Q2 Revenue of $50.7M, Up 92% Year-Over-Year, with $357M in Cash
- ImmunityBio Q2 Revenue Hits $50.7M, Up 92% YoY; Cash at $357M
Financial Snapshot
Short Interest & Short Volume
15.86 days to coverFINRA reported short interest of 125,408,192 shares in IBRX as of the September 15, 2026 settlement, a 0.2% decrease from the prior period — about 15.9 days to cover at its recent average daily volume. On October 2, 2026, 48.0% of IBRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.